Laïla El Khattabi, Pharm.D., Charlotte Dupont, Pharm.D., Nathalie Sermondade, M.D., Jean-Noël Hugues, M.D., Ph.D., Christophe Poncelet, M.D., Ph.D., Raphael Porcher, M.D., Ph.D., Isabelle Cedrin-Durnerin, M.D., Rachel Lévy, M.D., Ph.D., Christophe Sifer, M.D.
Volume 100, Issue 1, Pages 62-68, July 2013
To evaluate the potential benefit of intracytoplasmic morphologically selected sperm injection (IMSI) in patients selected for either severe teratozoospermia or repeated implantation failure after conventional intracytoplasmic sperm injection (ICSI).
Prospective nonrandomized observational study.
University hospital assisted reproduction unit.
Four hundred seventy-eight patients were enrolled to evaluate ICSI and IMSI results for two indications. The first group (T) was composed of patients with severe teratozoospermia (<10% normal spermatozoa in fresh ejaculated and selected semen, according to David classification) and no or one previous ICSI failure. In the second group (IF), patients with at least two previous failed ICSI attempts were enrolled in absence of severe male factor (>10% normal spermatozoa in fresh ejaculated semen and >20% in selected sperm).
ICSI/IMSI, biologic, and clinical data collection.
Main Outcome Measure(s):
Live-birth rate (LBR).
In group T, LBR was significantly higher when IMSI procedure was used compared with ICSI (38% [50/132] vs. 20% [25/126]). However, LBR observed in group IF was not significantly different between IMSI and ICSI procedures (21% [19/90] vs. 22% [28/130]).
IMSI procedure is a valuable option for patients with severe teratozoospermia at their first or second attempts, but it does not improve pregnancy rate in patients with repeated ICSI failures in the absence of severe male factor.
Read the full text at: http://www.fertstert.org/article/S0015-0282(13)00377-4/fulltext